Moderna
MRNA,
-0.04%

rose 4% in early premarket trade as it said late Tuesday that early-stage data suggests its COVID-19 vaccine can generate neutralizing antibodies in older and elderly adults at levels comparable to those in younger adults. The study was published in The New England Journal of Medicine. Moderna’s stock has surged 251% this year.

Read More

LEAVE A REPLY

Please enter your comment!
Please enter your name here